Dehnavi Sajad, Azad Farahzad Jabbari, Hoseini Reza Farid, Moazzen Nasrin, Tavakkol-Afshari Jalil, Nikpoor Amin Reza, Salmani Amir Abbas, Ahanchian Hamid, Mohammadi Mojgan
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
J Res Med Sci. 2019 Jun 25;24:51. doi: 10.4103/jrms.JRMS_543_18. eCollection 2019.
Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial.
Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention.
Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months ( = 0.001) and also at the end of intervention ( = 0.0001) comparing with the time zero.
Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion.
变应性鼻炎(AR)是全球最常见的变应性疾病。本研究在一项安慰剂对照临床试验中,评估了合生元对接受联合免疫疗法的AR患者中干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-17(IL-17)、转化生长因子β(TGF-β)和叉头框P3(FoxP3)基因表达的影响。
20例AR患者被随机分为合生元组和安慰剂组,并接受集群免疫疗法2个月。从外周血单个核细胞(PBMCs)中提取RNA,然后合成cDNA。随后,采用SYBR Green实时逆转录聚合酶链反应技术研究上述基因的表达。此外,患者完成了SNOT-22和小型鼻结膜炎生活质量问卷。在干预前以及干预后2个月和6个月对数据进行分析。
免疫疗法改善了临床症状和生活质量,但安慰剂组和合生元组之间无显著差异。IFN-γ、TGF-β和FoxP3的基因表达增加,而IL-4和IL-10的基因表达降低,但不显著。有趣的是,与安慰剂组相比,合生元组在2个月后(P = 0.001)以及干预结束时(P = 0.0001)与基线相比,IL-17的基因表达显著降低。
与安慰剂相比,服用合生元后IL-17基因表达显著降低,表明合生元在控制AR免疫发病机制中的重要性。建议进行更多样本的进一步研究。此外,建议评估合生元对未接受免疫疗法患者的影响,以得出更好的结论。